177 related articles for article (PubMed ID: 25380204)
1. [Immunostimulatory properties of mistletoe extracts and their application in oncology].
Wrotek S; Skawiński R; Kozak W
Postepy Hig Med Dosw (Online); 2014 Oct; 68():1216-24. PubMed ID: 25380204
[TBL] [Abstract][Full Text] [Related]
2. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
Felenda JE; Turek C; Stintzing FC
J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials.
Braedel-Ruoff S
Forsch Komplementmed; 2010 Apr; 17(2):63-73. PubMed ID: 20484913
[TBL] [Abstract][Full Text] [Related]
5. Immune modulation using mistletoe (Viscum album L.) extracts Iscador.
Büssing A
Arzneimittelforschung; 2006 Jun; 56(6A):508-15. PubMed ID: 16927532
[TBL] [Abstract][Full Text] [Related]
6. [Mistletoe in the treatment of cancer patients].
Rostock M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 May; 63(5):535-540. PubMed ID: 32211937
[TBL] [Abstract][Full Text] [Related]
7. [Vysorel/Isorel--cancer drug from Viscum album. Documentation No.20].
Kast A; Hauser SP
Schweiz Rundsch Med Prax; 1990 Mar; 79(11):332-4. PubMed ID: 2315589
[TBL] [Abstract][Full Text] [Related]
8. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy.
Kirsch A; Hajto T
J Altern Complement Med; 2011 Oct; 17(10):973-9. PubMed ID: 22010781
[TBL] [Abstract][Full Text] [Related]
9. Transcriptomic and proteomic insight into the effects of a defined European mistletoe extract in Ewing sarcoma cells reveals cellular stress responses.
Twardziok M; Meierhofer D; Börno S; Timmermann B; Jäger S; Boral S; Eggert A; Delebinski CI; Seifert G
BMC Complement Altern Med; 2017 Apr; 17(1):237. PubMed ID: 28454538
[TBL] [Abstract][Full Text] [Related]
10. Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro.
Kelter G; Fiebig HH
Arzneimittelforschung; 2006 Jun; 56(6A):435-40. PubMed ID: 16927523
[TBL] [Abstract][Full Text] [Related]
11. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study.
Grossarth-Maticek R; Kiene H; Baumgartner SM; Ziegler R
Altern Ther Health Med; 2001; 7(3):57-66, 68-72, 74-6 passim. PubMed ID: 11347286
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10.
Zarković N; Kalisnik T; Loncarić I; Borović S; Mang S; Kissel D; Konitzer M; Jurin M; Grainza S
Cancer Biother Radiopharm; 1998 Apr; 13(2):121-31. PubMed ID: 10850348
[TBL] [Abstract][Full Text] [Related]
13. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
Bar-Sela G; Gershony A; Haim N
Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
[TBL] [Abstract][Full Text] [Related]
14. Phytochemical profile and therapeutic potential of Viscum album L.
Nazaruk J; Orlikowski P
Nat Prod Res; 2016; 30(4):373-85. PubMed ID: 25813519
[TBL] [Abstract][Full Text] [Related]
15. Local reactions to treatments with Viscum album L. extracts and their association with T-lymphocyte subsets and quality of life.
Büssing A; Tröger W; Stumpf C; Schietzel M
Anticancer Res; 2008; 28(3B):1893-7. PubMed ID: 18630477
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiles of different breast cancer cells compared with their responsiveness to fermented mistletoe (Viscum album L.) extracts Iscador from oak (Quercus), pine (Pinus), white fir (Abies) and apple tree (Malus) in vitro.
Eggenschwiler J; Patrignani A; Wagner U; Rehrauer H; Schlapbach R; Rist L; Ramos MH; Viviani A
Arzneimittelforschung; 2006 Jun; 56(6A):483-96. PubMed ID: 16927530
[TBL] [Abstract][Full Text] [Related]
17. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
[TBL] [Abstract][Full Text] [Related]
18. Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador.
Grossarth-Maticek R; Ziegler R
Arzneimittelforschung; 2007; 57(10):665-78. PubMed ID: 18074761
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant Cancer Biotherapy by Viscum Album Extract Isorel: Overview of Evidence Based Medicine Findings.
Sunjic SB; Gasparovic AC; Vukovic T; Weiss T; Weiss ES; Soldo I; Djakovic N; Zarkovic T; Zarkovic N
Coll Antropol; 2015 Sep; 39(3):701-8. PubMed ID: 26898069
[TBL] [Abstract][Full Text] [Related]
20. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.
Kienle GS; Grugel R; Kiene H
BMC Complement Altern Med; 2011 Aug; 11():72. PubMed ID: 21871125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
